BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38631227)

  • 1. Oligomeric proanthocyanidins ameliorates osteoclastogenesis through reducing OPG/RANKL ratio in chicken's embryos.
    Yu G; Fu X; Gong A; Gu J; Zou H; Yuan Y; Song R; Ma Y; Bian J; Liu Z; Tong X
    Poult Sci; 2024 Mar; 103(6):103706. PubMed ID: 38631227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overloaded Orthopedic Force Induces Condylar Subchondral Bone Absorption by Stimulating Rat Mesenchymal Stem Cells Differentiating into Osteoclasts via mTOR-Regulated
    Tian Y; Chen J; Yan X; Ren D; Liu M; Zhang Q; Zhang Q; Yuan X
    Stem Cells Dev; 2021 Jan; 30(1):29-38. PubMed ID: 33176606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.
    Ozaki Y; Koide M; Furuya Y; Ninomiya T; Yasuda H; Nakamura M; Kobayashi Y; Takahashi N; Yoshinari N; Udagawa N
    PLoS One; 2017; 12(9):e0184904. PubMed ID: 28937990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
    de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
    J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.
    Kang JH; Ko HM; Moon JS; Yoo HI; Jung JY; Kim MS; Koh JT; Kim WJ; Kim SH
    J Dent Res; 2014 Nov; 93(11):1116-23. PubMed ID: 25256714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts.
    Lee DW; Kwon JY; Kim HK; Lee HJ; Kim ES; Kim HJ; Kim HJ; Lee HB
    Int J Med Sci; 2018; 15(7):723-729. PubMed ID: 29910677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine osteoclasts secrete serine protease HtrA1 capable of degrading osteoprotegerin in the bone microenvironment.
    Ochiai N; Nakachi Y; Yokoo T; Ichihara T; Eriksson T; Yonemoto Y; Kato T; Ogata H; Fujimoto N; Kobayashi Y; Udagawa N; Kaku S; Ueki T; Okazaki Y; Takahashi N; Suda T
    Commun Biol; 2019; 2():86. PubMed ID: 30854478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
    Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
    Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diverse osteoclastogenesis of bone marrow from mandible versus long bone.
    Chaichanasakul T; Kang B; Bezouglaia O; Aghaloo TL; Tetradis S
    J Periodontol; 2014 Jun; 85(6):829-36. PubMed ID: 24003963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
    Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
    Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.
    Chen ST; Kang L; Wang CZ; Huang PJ; Huang HT; Lin SY; Chou SH; Lu CC; Shen PC; Lin YS; Chen CH
    Molecules; 2019 Jan; 24(1):. PubMed ID: 30609798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18β-Glycyrrhetinic Acid Inhibits Osteoclastogenesis
    Chen X; Zhi X; Yin Z; Li X; Qin L; Qiu Z; Su J
    Front Pharmacol; 2018; 9():647. PubMed ID: 29973878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
    Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
    J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.